As over 80% of individuals with T2D are obese (Nadler et al. 2000), PTP1B inhibition may be a potential strategy for a therapeutic target of type 2 diabetes through its links with obesity. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.